Oncology Other denied as non-formulary by Blue Cross Blue Shield?

For Anthem Blue Cross Blue Shield Marketplace (Individual & Commercial) members, oncology drugs administered under the medical benefit are delegated to Carelon Medical Benefits Management (formerly AIM Specialty Health) for prior authorization review. Carelon uses an evidence- and value-based approach utilizing cancer treatment pathways, provider-preferred clinical review, and enhanced reimbursement and pathway adherence reporting, covering approximately 85% of spending on cancer drugs across therapeutic and supportive drugs. Carelon Cancer Treatment Pathways are cancer treatment regimens intended to support quality cancer care and reduce unneeded variation in care and cost, developed through a rigorous process of integrating evidence-based literature with physician practice guidelines. Pathways identify a subset of regimens supported by clinical evidence and practice guidelines, selected based on clinical benefit (efficacy), safety/side effects (especially those leading to hospitalizations and impacting quality of life), strength of national guideline recommendations, and cost of regimens. Off-pathway requests are reviewed individually: the platform approves requests that align with policy and pathways, and board-certified medical oncologists and nurses consult on off-pathway requests and alert providers to enhanced reimbursement opportunities. For some health plans, requested services are reviewed in accordance with client medical policies and clinical guidelines; if a request is received that is not a Carelon Pathway regimen, it may be reviewed and authorized if determined to be medically necessary, with reference to NCCN Clinical Practice Guidelines in Oncology. Critical elements include confirming the diagnosis based on a complete evaluation including history, physical examination, relevant laboratory studies, diagnostic testing, and response to prior therapeutic intervention, with anticipated benefit outweighing potential harms. Self-administered/oral oncology drugs under the pharmacy benefit are reviewed against CarelonRx clinical criteria approved by the CarelonRx Pharmacy and Therapeutics Committee, an independent external committee of practicing physicians, pharmacists, and clinicians from leading academic medical centers with expertise in evidence-based medicine across all major clinical specialties.

- Carelon's own framework permits off-pathway approval when medically necessary: the treating oncologist determines if a Pathway regimen is the best option or whether, given the patient's unique circumstances, another regimen is a better choice, and non-Pathway requests may be authorized if determined to be medically necessary, referencing NCCN Clinical Practice Guidelines in Oncology. - Cite the specific NCCN Clinical Practice Guideline (Category 1 or 2A recommendation) supporting the requested regimen for the patient's histology, stage, and biomarker status — Carelon explicitly references NCCN as an authoritative source for medical necessity determinations. - Submit biomarker/pathology reports (e.g., NGS, IHC, FISH) confirming the targetable alteration required by the FDA label or NCCN guideline; Carelon requires confirmation of the diagnosis based on complete evaluation including review of relevant laboratory studies and diagnostic testing. - For step-therapy denials, document contraindication, intolerance, or prior failure of preferred agents; step therapy requires that the member has tried an alternative therapy first, or that the prescriber has clinically documented why the member cannot take the alternative therapy. - Demonstrate that benefit outweighs harm and delay would worsen outcomes: the anticipated benefit of the recommended intervention is likely to outweigh any potential harms, including from delay or decreased access to treatment. - Invoke clinician authority and individualization: medical necessity decisions may change as new information is provided or based on unique aspects of the patient's condition, and the treating clinician has final authority and responsibility for treatment decisions and for justifying medical necessity. - For Marketplace ACA plans, cite the ACA's essential health benefit protections and the plan's obligation to follow recognized compendia (NCCN Drugs & Biologics Compendium, AHFS, Micromedex DrugDex) for off-label oncology indications, which Carelon's pathway framework already incorporates via NCCN alignment.

## Why BCBS May Deny an Oncology Drug as "Non-Formulary" and How to Appeal

Blue Cross Blue Shield formularies — the lists of drugs a plan covers at standard cost-sharing — may not include every FDA-approved oncology medication, particularly newer agents, drugs used in off-label indications, or medications that have not yet completed the plan's formulary review cycle. A non-formulary denial means the plan will not cover the drug at its standard benefit tier, but it does not mean the drug cannot be covered at all. A formulary exception process exists specifically for this situation.

### Why This Denial Is Appealable

Formulary exception requests and non-formulary appeals succeed when your prescriber documents that no formulary alternative is clinically appropriate for your specific diagnosis and clinical situation. In oncology, formulary alternatives for a given cancer type are rarely interchangeable — the specific drug prescribed may be selected based on your tumor's biomarker profile, your treatment history, or toxicity considerations unique to your case. That specificity is the heart of a non-formulary exception appeal.

### Federal Appeal Framework

• Formulary exception request: Most plans have a separate, faster exception process. Submit this first — your prescriber requests a formulary exception, and the plan applies medical-necessity criteria.
• Internal appeal: If the exception request is denied, file a formal internal appeal within the period stated on your denial notice. ERISA §503 requires a full-and-fair review.
• External review (ACA §2719): After exhausting internal appeals, you may request independent external review, typically within four months of the final internal denial.
• Expedited option: Request expedited review if delay would jeopardize active treatment. Expedited external review typically resolves within 72 hours.

### Documentation to Gather

1. Prescriber exception letter: A letter from your oncologist explaining why no formulary alternative is clinically appropriate for your specific diagnosis, stage, and biomarker profile. 2. Formulary alternative assessment: If BCBS has identified formulary alternatives, your oncologist should address each one — explaining why it is not appropriate given your clinical situation (different mechanism, contraindication, prior failure, biomarker mismatch, etc.). 3. Diagnosis, staging, and biomarker records: Documentation that establishes the clinical specificity of your case and why the prescribed agent is uniquely appropriate. 4. Prior-treatment history: Evidence that formulary alternatives have already been tried or that they are not appropriate options at this stage of treatment. 5. BCBS formulary exception criteria: Request the written criteria so you can address each point directly.

### Criteria-Mapping Approach

| Exception Criterion | Supporting Documentation | |---|---| | No formulary alternative is clinically appropriate | [Oncologist letter addressing each alternative] | | Formulary alternative previously failed or contraindicated | [Chart history, prescriber letter] | | Drug is medically necessary for this specific indication | [Diagnosis, biomarker, staging records] |

Formulary exception approvals in oncology are common when the prescriber letter is specific and addresses the plan's alternatives directly. Vague letters citing "clinical judgment" alone are less effective than letters that name each formulary alternative and explain why it does not apply.